We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.34B
AUM Growth
+$16.4M
Cap. Flow
-$1.65M
Cap. Flow %
-0.12%
Top 10 Hldgs %
51.3%
Holding
73
New
15
Increased
18
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$54.1M
2
BSX icon
Boston Scientific
BSX
+$40.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$40.2M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$34.8M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$22.4M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$49M
2
CMRX
Chimerix, Inc.
CMRX
+$40.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.8M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$33.8M
5
INCY icon
Incyte
INCY
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Miscellaneous 9.9%
3 Communication Services 1.56%
4 Industrials 0.57%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$294K 0.02%
2,087
-1,124
-35% -$153K
DBVT
52
DBV Technologies
DBVT
$851M
$290K 0.02%
799
-52,483
-99% -$18.3M
ADVM
53
DELISTED
Adverum Biotechnologies
ADVM
$231K 0.02%
2,424
-72,418
-97% -$6.36M
AXDX
54
DELISTED
Accelerate Diagnostics
AXDX
$215K 0.02%
+1,000
New +$183K
CSLT
55
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$44K ﹤0.01%
10,229
-724,168
-99% -$3.11M
AUPH icon
56
Aurinia Pharmaceuticals
AUPH
$2.17B
$41K ﹤0.01%
+16,610
New +$45.1K
BMRN icon
57
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-368,775
Closed -$38.8M
CERS icon
58
Cerus
CERS
$534M
– –
-1,603,427
Closed -$7.28M
CLDX icon
59
Celldex Therapeutics
CLDX
$3.07B
– –
-130,268
Closed -$20.6M
DVAX
60
DELISTED
Dynavax Technologies
DVAX
– –
-724,348
Closed -$17.8M
JAZZ icon
61
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-1,769
Closed -$235K
NGNE icon
62
Neurogene
NGNE
$732M
– –
-25,715
Closed -$7.24M
PPH icon
63
VanEck Pharmaceutical ETF
PPH
$993M
– –
-6,500
Closed -$409K
RGNX icon
64
Regenxbio
RGNX
$638M
– –
-277,000
Closed -$6.1M
TNET icon
65
TriNet
TNET
$3.23B
– –
-639,186
Closed -$10.7M
CMRX
66
DELISTED
Chimerix, Inc.
CMRX
– –
-1,067,978
Closed -$40.8M
RAD
67
DELISTED
Rite Aid Corporation
RAD
– –
-403,570
Closed -$49M
INFI
68
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-590,100
Closed -$4.99M
CERN
69
DELISTED
Cerner Corp
CERN
– –
-3,563
Closed -$214K
GNCA
70
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-11,456
Closed -$628K
NXTM
71
DELISTED
NxStage Medical Inc.
NXTM
– –
-11,800
Closed -$186K
ZSPH
72
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-514,107
Closed -$33.8M
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2015 Portfolio in Review

As of Q4 2015, Redmile Group held 73 positions worth $1.34B, up 1.2% from $1.32B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Redmile Group's Q4 2015 filing shows 15 new, 18 increased, 22 reduced and 16 closed positions. Its largest new stake was Boston Scientific: 2,251,020 shares worth $41.5M. The largest sale was Rite Aid Corporation, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q4 2015 buy was Boston Scientific: 2,251,020 shares worth $41.5M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2015, an estimated $54.1M increase.
  • Redmile Group's biggest Q4 2015 reduction was Incyte, cutting an estimated $28.5M.
  • Redmile Group fully exited Rite Aid Corporation in Q4 2015, selling an estimated $49M.
  • Redmile Group's ten largest holdings make up 51% of its $1.34B portfolio in Q4 2015.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2015.
  • Redmile Group's portfolio value rose 1.2% quarter-over-quarter to $1.34B.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.